Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

An autoinjector to administer Leqembi to patients with early-stage Alzheimer’s disease had high degrees of satisfaction for ...

As Alzheimer’s Awareness Month comes to an end, Florida State University researchers are continuing efforts to better ...

High levels of calcium are toxic to cells and contribute to loss of neurons in Alzheimer's disease. A new study published in ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Researchers have conducted the first study evaluating the impact of obesity on Alzheimer's disease blood biomarkers (BBMs).

Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...

Scientists are finding that brain immune cells known as microglia with a specific mutation (at right) stayed young and ...